Collectively, our studies demonstrated that inhibition of HDAC6 and HDAC8 through selective inhibitors ACY-241 and PCI-34051 synergistically increases the stability of p53, which may contribute to the enhancement in apoptosis and inhibition of metastasis in wild-type p53 ovarian cancer cells. Here, HDAC8 is linked to ovarian carcinoma.